These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29991523)

  • 41. Therapeutic developments in the therapy of heart failure: lessons to be learned.
    Parker JD
    Eur Heart J; 2015 Aug; 36(30):1952-4. PubMed ID: 26088390
    [No Abstract]   [Full Text] [Related]  

  • 42. Heart failure in 2015: Better results from prevention than from additional treatment.
    Køber L
    Nat Rev Cardiol; 2016 Feb; 13(2):75-7. PubMed ID: 26727301
    [No Abstract]   [Full Text] [Related]  

  • 43. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
    Pham AQ; Patel Y; Gallagher B
    J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
    Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?
    Ruggenenti P; Remuzzi G
    Eur J Heart Fail; 2015 May; 17(5):468-71. PubMed ID: 25914256
    [No Abstract]   [Full Text] [Related]  

  • 47. [« ARNI » (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how?].
    Russo-Vorms L; Meyer P; Reny JL
    Rev Med Suisse; 2019 Oct; 15(667):1882-1886. PubMed ID: 31617977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Barghash MH; Desai AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
    Packer M; Claggett B; Lefkowitz MP; McMurray JJV; Rouleau JL; Solomon SD; Zile MR
    Lancet Diabetes Endocrinol; 2018 Jul; 6(7):547-554. PubMed ID: 29661699
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart failure--does it matter whether LVEF is reduced?
    Cleland JG; Clark AL
    Lancet; 2012 Oct; 380(9851):1363-5. PubMed ID: 22932711
    [No Abstract]   [Full Text] [Related]  

  • 51. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure.
    Lainscak M; Coats AJ
    Int J Cardiol; 2016 Jun; 212():187-9. PubMed ID: 27038730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
    Simpson J; Jhund PS; Silva Cardoso J; Martinez F; Mosterd A; Ramires F; Rizkala AR; Senni M; Squire I; Gong J; Lefkowitz MP; Shi VC; Desai AS; Rouleau JL; Swedberg K; Zile MR; McMurray JJV; Packer M; Solomon SD;
    J Am Coll Cardiol; 2015 Nov; 66(19):2059-2071. PubMed ID: 26541915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [No available].
    Rioux JD
    Perspect Infirm; 2016; 13(2):58. PubMed ID: 27156290
    [No Abstract]   [Full Text] [Related]  

  • 55. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
    Braunwald E
    Eur Heart J; 2016 Mar; 37(9):745-6. PubMed ID: 26933120
    [No Abstract]   [Full Text] [Related]  

  • 58. Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
    Hsiao R; Greenberg B
    Curr Heart Fail Rep; 2016 Aug; 13(4):172-80. PubMed ID: 27271564
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
    Braunwald E
    J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.
    Solomon SD; Claggett B; Packer M; Desai A; Zile MR; Swedberg K; Rouleau J; Shi V; Lefkowitz M; McMurray JJV
    JACC Heart Fail; 2016 Oct; 4(10):816-822. PubMed ID: 27395349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.